Detecting lung cancer early and predicting treatment response using a blood test.
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay
This study is testing a new blood test that can help find lung cancer early and see how well patients might respond to treatment, making it easier and less invasive than traditional methods.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10912448 on NIH RePORTER |
What this research studies
This research focuses on developing a non-invasive liquid biopsy assay that can detect lung cancer at an early stage and predict how well patients will respond to immunotherapy. By analyzing tumor-derived exosomes found in blood samples, the study aims to improve the accuracy of lung cancer diagnosis and reduce the need for invasive procedures like biopsies. The approach combines advanced biosensing techniques with existing imaging and risk factor data to provide a comprehensive monitoring solution for lung cancer patients. This innovative method seeks to enhance patient outcomes by enabling timely and effective treatment decisions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for lung cancer, such as smokers or those with a family history of the disease.
Not a fit: Patients with advanced lung cancer who are already undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier lung cancer detection and more personalized treatment plans, ultimately improving survival rates.
How similar studies have performed: Previous research has shown promise in using liquid biopsies for cancer detection, indicating that this approach could be effective for lung cancer as well.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Wu, Yun — State University of New York at Buffalo
- Study coordinator: Wu, Yun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.